Diagnostic Science Liaison
by AstraZeneca in Pharmaceuticals
The Diagnostic Science Liaison (Oncology) at AstraZeneca is a field-based diagnostics expert responsible for advancing precision oncology by enabling timely and accurate biomarker testing and optimizing patient identification across the care pathway. Reporting to the Diagnostics Manager, the role acts as the primary scientific point of contact for molecular diagnostics across assigned institutions and regions, building partnerships with healthcare professionals (HCPs), pathology and laboratory networks, molecular genetics stakeholders, pulmonology teams, laboratory leadership, hospital administrators, policy makers, and payers to improve access, quality, and utilization of diagnostic testing. The position requires deep scientific knowledge of biomarker testing and operational understanding of pre-analytical, analytical, and post-analytical testing processes. The Diagnostic Science Liaison conducts balanced scientific exchange on biomarker biology, testing modalities, clinical pathways, and outcomes evidence while identifying barriers and opportunities within the diagnostic ecosystem. The role supports availability and correct use of in-market companion diagnostics and complementary diagnostics, fosters sustainable high-quality testing solutions, and contributes to pathway optimization across the patient journey. Responsibilities include mapping patient and sample journeys, identifying testing gaps, supporting lab readiness and testing capacity, and collaborating cross-functionally to optimize testing adoption. The role also supports local evidence generation including real world evidence (RWE), biomarker prevalence, testing quality, and turnaround time studies, while contributing to medical and diagnostic strategy development. The position requires adherence to AstraZeneca compliance standards, corporate governance, confidentiality requirements, patient safety standards, and regulatory guidelines, while supporting education initiatives, stakeholder engagement, and clinical study feasibility within oncology diagnostics.